MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Myriad Genetics Market Cap 2011-2026 | MYGN
As of May 15, 2026 Myriad Genetics has a market cap of $ 335 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Myriad Genetics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 409 M | 973 M | 1.8 B | 1.74 B | 2.21 B | 1.49 B | 2 B | 2.97 B | 1.62 B | 2.17 B | 2.4 B | 2.78 B | 2.43 B | 2.19 B | 1.91 B | 1.72 B | 3.45 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.45 B | 409 M | 2.02 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 18.56 | 10.74 % | $ 196 M |  China |
 |
Agilent Technologies
A
|
42 B | - | - | $ 34.4 B |  USA |
 |
Castle Biosciences
CSTL
|
472 M | $ 18.88 | 4.02 % | $ 547 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 16.19 | 1.44 % | $ 490 M | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
993 M | $ 20.49 | -0.58 % | $ 1.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 419.17 | -1.08 % | $ 12.1 B | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
5.12 B | - | - | $ 6.5 B | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 041.91 | 1.75 % | $ 21.5 B |  Schweiz |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.63 | 1.87 % | $ 2.17 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.36 | 1.21 % | $ 1.07 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 18.93 | 1.39 % | $ 424 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 196.91 | 0.81 % | $ 19.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 159.12 | -2.29 % | $ 7.89 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.3 B | $ 25.5 | -0.51 % | $ 24.2 B |  Niderland |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Personalis
PSNL
|
431 M | $ 6.71 | 5.01 % | $ 599 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 98.66 | 0.19 % | $ 12.4 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 5.82 | 5.82 % | $ 243 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 117.09 | -0.25 % | $ 9.66 B |  Irlanda |
 |
Illumina
ILMN
|
16.4 B | $ 143.24 | -1.21 % | $ 22.8 B | USA |
 |
Soleno Therapeutics
SLNO
|
2.08 B | $ 52.99 | 0.08 % | $ 2.69 B | USA |
 |
Trinity Biotech plc
TRIB
|
194 M | $ 0.58 | -1.08 % | $ 208 M | Irlanda |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
1.56 B | $ 52.95 | -2.65 % | $ 3.17 B | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.41 | 7.11 % | $ 5.54 M | USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 448.21 | 0.49 % | $ 169 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 254.02 | -0.16 % | $ 21.1 B | USA |
 |
Waters Corporation
WAT
|
19.7 B | $ 333.21 | -0.51 % | $ 19.8 B | USA |
 |
Celcuity
CELC
|
5.37 B | $ 134.72 | 8.23 % | $ 6.3 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 8.43 | -2.99 % | $ 1.83 B | USA |